CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net income	$ 642,407	$ 481,062
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	75,845	51,999
Non-cash compensation expense	405,320	300,657
Other non-cash charges and expenses, net	13,586	34,919
Increase (Decrease) in Deferred Income Taxes	(190,327)	(65,975)
Changes in assets and liabilites
Increase in Sanofi, Bayer, and trade accounts receivable	(176,079)	(462,943)
Increase in Inventories	(99,706)	(66,254)
Decrease (increase) in prepaid expenses and other assets	34,857	(13,223)
Increase in deferred revenue	282,176	624,063
Increase in accounts payable, accrued expenses and other liabilities	107,438	164,652
Total adjustments	453,110	567,895
Net cash provided by operating activities	1,095,517	1,048,957
Cash flows from investing activities:
Purchases of marketable securities	(606,153)	(550,142)
Sales or maturities of marketable securities	192,091	265,995
Capital expenditures	(361,486)	(500,154)
Net cash used in investing activities	(775,548)	(784,301)
Cash flows from financing activities:
Proceeds in connection with facility lease obligations	3,232	26,405
Repayments of convertible senior notes	(12,650)	(146,007)
Payments in connection with deduction of outstanding warrants	(242,117)	(523,487)
Proceeds from issuance of Common Stock	89,777	150,423
Payments in connection with Common Stock tendered for employee tax obligations	(46,954)	(71,673)
Excess tax benefit from stock-based compensation	0	305,551
Net cash used in by financing activities	(208,712)	(258,788)
Net increase in cash and cash equivalents	111,257	5,868
Cash and cash equivalents at beginning of period	809,102	648,719
Cash and cash equivalents at end of period	$ 920,359	$ 654,587